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SUMMARY 
Pulmonary hypertension (PH) is an umbrella term used for the haemodynamic sequelae of 
many different conditions that all result in elevation of the mean pulmonary arterial pressure 
(exceeding 25 mmHg at rest), where chronic hypoxia is considered a major trigger. PH is a 
severe condition that leads to right heart failure and death when left untreated. It is 
characterized by the triad of vasoconstriction, microthrombotic events, and remodelling of the 
small pulmonary arteries. Of these changes, vascular remodelling due to the proliferation and 
migration of vascular smooth muscle and endothelial cells, causing progressive obliteration of 
the vascular lumen, is arguably the most important pathogenetic factor in PH and, since no 
therapy is available that directly targets remodelling yet, still defines chronicity and 
incurability of the disease. Therefore, novel concepts that unravel the pathobiology 
underlying the process of vascular remodelling and, as such, could provide the basis for a new 
generation of treatment strategies ("reverse remodelling") are utterly needed. Chronic 
exposure to hypoxia represents one of the best-established pathogenic models for pulmonary 
arterial vasoconstriction and vascular remodelling. In this regard, the aquaporins (AQPs), a 
class of membrane water channels responsible for rapid trans-epithelial fluid transport, appear 
as a novel interesting target. The mammalian AQP family consists of 13 different subsets, 
which are expressed in multiple organs, including the lungs, and are involved in additional 
physiological processes such as cell migration, proliferation and angiogenesis. It has been 
shown that hypoxia can modulate the expression of AQP1 in the lungs of mice indicating an 
important physiological role of AQP1 in the adaption to oxygen depletion. Along that line, a 
recent work demonstrated the presence of AQP1 in pulmonary vasculature of rats and the 
regulation of AQP1 by chronic exposure to hypoxia. In a previous study the regulation of rat 
pulmonary smooth muscle migration by AQP1 was assessed and was found to be essential for 
hypoxia-induced smooth muscle migration. 
Since the interplay between AQP1, hypoxia and PH has not been directly addressed so far, the 
present thesis was conducted to investigate the physiological role of AQP1 in the 
pathobiology of vascular remodelling in hypoxia-induced PH. This study was designed to 
characterize the expression and function of AQP1 in human vascular cells derived from 
pulmonary arteries and in the mouse model of hypoxia-induced PH. By focusing on AQP1, 
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we expected novel insights into the pathogenesis of the disease that might lead to the 
development of novel therapies.  
In this PhD thesis, I could provide evidence that (i) exposure of human pulmonary vascular 
cells to hypoxia significantly induced the expression of AQP1. Similarly, (ii) levels of AQP1 
were found to be upregulated in lungs of mice with hypoxia-induced PH. The functional role 
of AQP1 was further tested in human pulmonary artery smooth muscle cells (HPASMC) 
demonstrating that (iii) depletion of AQP1 with GapmeR inhibitors reduced the migratory 
potential, proliferation, and, conversely, induced apoptosis of these cells. Along that line, (iv) 
transient transfection with a vector overexpressing AQP1 led to enhanced proliferation and 
migration rates. This effect was associated with (v) higher expression of the tumour 
suppressor gene p53 when AQP1 was silenced. Conversely, expression levels of p53 were 
found to be decreased in HPASMC exposed to hypoxia. Using the mouse model of hypoxia-
induced PH, (vi) application of GapmeR inhibitors targeting AQP1 abated the hypoxia-
induced upregulation of AQP1 and, of note, reversed PH by decreasing both right ventricular 
pressure and right ventricular hypertrophy back to the levels of control mice. 
In conclusion, to the best of our knowledge, this is the first report on therapeutic intervention 
of AQP1 in the context of PH. Our data suggest an important functional role of AQP1 in the 
pathobiology of hypoxia-induced PH. Since vascular remodelling is currently not sufficiently 
addressed by PH therapies, these findings have implications both for our pathogenetic 
understanding and novel therapeutic approaches. 
 
 
 IV 
ZUSAMMENFASSUNG 
Das Krankheitsbild der pulmonalen Hypertonie (PH) betrifft die kleinen Blutgefässe in der 
Lunge und umfasst eine Vielzahl an Erkrankungen, die zu einer drastischen Druckerhöhung 
im Lungenkreislauf (mittlerer pulmonal-arterieller Druck von ≥ 25 mmHg) und innert 
weniger Jahre zu einer rechtsventrikulären Insuffizienz und schlussendlich zum Tod führt. 
Interessanterweise münden die meisten Auslöser der pulmonalen Hypertonie in eine 
gemeinsame pathogenetische Endstrecke. Diese besteht aus einer Trias von übermässiger 
Engstellung der Gefässe (Vasokonstriktion) in der Lunge, lokale kleine Blutgerinnseln 
(Mikrothrombosen) und einem charakteristischen Gefässumbau (Remodelling) der kleinen 
pulmonalen Arterien aufgrund exzessiver Proliferation und Migration der pulmonalen glatten 
Muskel- und Endothelzellen. Trotz neuer Therapieansätze bleibt die PH eine nicht heilbare 
Erkrankung, insbesondere weil das Remodelling, welches die Irreversibilität und die 
Chronizität der Erkrankung definiert, bisher nicht therapeutisch adressiert werden konnte. 
Neue Erkenntnisse aus der Pathogenese des Gefässumbaus sind deshalb für die Entwicklung 
potentiell kausaler Therapieansätze von eminenter Wichtigkeit. Zustände von niedrigem 
Sauerstoffgehalt (Hypoxie) gehören zu den wichtigsten pathogenetischen Faktoren, welche 
eine pulmonale Hypertonie auslösen, sie bilden auch die Grundlage für das etablierte 
experimentelle Mausmodell der Hypoxie-induzierten pulmonalen Hypertonie. In diesem 
Kontext sind Aquaporine – eine Familie von 13 membranständigen Wasserkanälen in 
Säugetieren, die in unterschiedlichen Zelltypen und Organen, so auch z.B. der Lunge, 
vorkommen – wiederholt als interessante Faktoren beschrieben worden: sie, vor allem 
Aquaporin 1 (AQP1), regulieren zusätzlich verschiedene physiologische Prozesse wie 
Zellproliferation, Zellmigration, und Angiogenese, welche auch im Zusammenhang mit dem 
pulmonalen Gefässumbau eine Rolle spielen. Wie in Versuchen an Ratten und 
Zellkulturexperimenten in glatten Muskelzellen gezeigt wurde, wird die Expression von 
AQP1 zudem durch Hypoxie gesteuert und stabilisiert. AQP1 ist überdies von immenser 
Wichtigkeit im Zusammenhang von Hypoxie-induzierter Migration der glatten Muskelzellen. 
Basierend auf diesen Daten gehen wir von einer bisher unbeschriebenen, pathogenetischen 
Rolle von AQP1 beim Remodelling in der Hypoxie-induzierten pulmonalen Hypertonie aus, 
weil das Zusammenspiel zwischen AQP1, Hypoxie und PH noch nicht direkt adressiert 
wurde. Der Schwerpunkt meiner Doktorarbeit war die Erforschung der Expression und 
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funktionellen Charakterisierung von AQP1 in Zellkulturexperimenten und im Mausmodell 
der Hypoxie-induzierten PH. Unserem Ansatz nach erwarten wir neue Erkenntnisse im 
Bereich der Pathogenese dieser Krankheit, welche später vielleicht zur Entwicklung neuer 
Therapieansätze führen könnte. 
Mit meiner PhD Dissertation konnte ich aufzeigen, dass sich (i) die Expression von AQP1 in 
menschlichen pulmonalen Gefässzellen signifikant erhöhte, nachdem man diese Hypoxie 
ausgesetzt hat. Des Weiteren war die (ii) AQP1 Expression auch in Lungen von Mäusen mit 
Hypoxie-induzierter PH aufreguliert. Die funktionelle Rolle von AQP1 wurde zusätzlich in 
menschlichen pulmonalen glatten Muskelzellen (HPASMC) getestet. Mit diesen 
Experimenten konnte gezeigt werden, dass die (iii) Inhibierung von AQP1 durch neue anti-
sense-orientierte DNA Moleküle (GapmeRs) die Proliferation und Migration gehemmt hat, 
zur selben Zeit jedoch die Apoptose gestiegen ist. Gegenteilige Resultate wurden erzielt, 
wenn (iv) AQP1 durch transiente Transfektion überexprimiert wurde: Proliferation und 
Migration von HPASMC waren erhöht. Bei Inhibition von AQP1 war dieser Effekt mit einer 
(v) hochregulierten Expression des Tumorsuppressorgens p53 verbunden. Um die 
physiologische Bedeutung von AQP1 für den Krankheitsverlauf der PH zu untersuchen, 
wurde das Mausmodell der Hypoxie-induzierten PH verwendet. Die (vi) Applikation von 
GapmeRs führte dabei zur Antagonisierung von AQP1 auf das Niveau normoxischer 
Kontrollmäuse. Physiologische Untersuchungen konnten dabei zeigen, dass sowohl die 
Erhöhung des rechtventrikulären Druckes als auch die für PH charakteristische 
rechtsventrikuläre Hypertrophie durch Inhibierung von AQP1 signifikant reduziert wurde. 
Nach bestem Wissen wurde mit dieser Doktorarbeit zum ersten Mal der Zusammenhang 
zwischen AQP1 und PH aufgezeigt und beschrieben. Meine Daten untermauern die 
Hypothese, dass AQP1 eine entscheidende funktionelle Rolle in der Pathobiologie der 
Hypoxie-induzierten PH spielt. Da das Remodelling für therapeutische Ansätze bisher nicht 
zugänglich ist und auch die Unheilbarkeit der Erkrankung definiert, haben diese Resultate 
Auswirkungen sowohl für unser pathogenetisches Verständnis als auch potenziell neue 
Therapiemöglichkeiten. GapmeRs könnten einen neuen vielversprechenden Ansatz zur 
Behandlung von PH darstellen. 
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 INTRODUCTION 1
1.1 PULMONARY HYPERTENSION 
Pulmonary hypertension (PH) is haemodynamically defined as an increase in mean 
pulmonary arterial pressure (mPAP) exceeding 25 mmHg at rest or 30 mmHg during physical 
activity.1, 2 It was first described by Ernst von Romberg in 1891.3 The sustained increase in 
blood pressure in the lung vasculature leads to exercise limitation and shortness of breath, 
fatigue, syncope, and, when left untreated, to right heart failure and death.4 Pulmonary arterial 
hypertension (PAH), the most common form of PH, is a rare disorder with an estimated 
incidence of approximately 2-3 cases per million per year.5 
In 1973, the World Health Organization (WHO) prompted a first proposal on a clinical 
classification scheme for PH and ever since, the classification has gone through a series of 
changes, the most recent revision occurring during the 5th World Symposium on Pulmonary 
Hypertension held in Nice, France, in 2013.6, 7 Five groups of disorders that cause PH were 
identified (Group 1 to Group 5) (Table 1), which are based on clinical and pathobiological 
features, similar haemodynamic characteristics as well as similar therapeutic options. 
 
Table 1. Clinical classification of pulmonary hypertension (PH) based on the 5th World Symposium on 
Pulmonary Hypertension (Nice, France; 2013). Main modifications to the previous Dana Point classification 
(California, USA; 2008) are in bold. Reproduced from Simoneau et al.6 
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Although PH is a disease of various origins with a life-threatening outcome when left 
untreated,1, 8 chronic hypoxia is considered a major trigger.9 Exposure to chronic hypoxia 
occurs not only in high-altitude residents but also in patients suffering from chronic diseases 
associated with reduced oxygen transport capacity during wakefulness and/or sleep such as 
congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), sleep apnoea 
(SA), and also cancer.10-13 Therefore, PH associated with hypoxia or chronic diseases of the 
respiratory system are regarded as separate entity and thus Group 3 of the Nice classification 
on PH. 
Whatever the initial cause and despite the fact that not all types of PH share a common 
aetiology, all five groups of PH are accurately defined by a progressive increase in pulmonary 
vascular resistance, caused by the triad of vasoconstriction, in situ micro-thrombosis and 
excessive vascular remodelling of the small pulmonary arteries.8, 14, 15 Endothelial cells (ECs) 
play a key role since a potential cause of the pathophysiological changes in PH most likely 
includes endothelial dysfunction leading to a homeostatic imbalance in the endothelium-
mediated secretion of vasoactive substances.16 A typical and frequently observed pattern in 
PH is that the release of vasoconstrictors and the expression of their receptors are upregulated 
whereas vasodilators are downregulated. In this context, the contraction of smooth muscle 
cells (SMCs) surrounding the small arteries is mainly associated with an increased expression 
of the vasoconstrictor endothelin-1 (ET-1) in the vasculature, whereas the release of the 
vasodilators nitric oxide (NO) and prostacyclin (e.g. prostaglandin I2) from ECs is reduced.14 
Furthermore, reduced oxygenation regarding ECs also has an influence on their proliferation 
and migration, survival, expression of metabolites and inflammatory response.17, 18 Whereas 
acute hypoxia increases pulmonary pressure by calcium-mediated vasoconstriction of 
pulmonary vascular SMCs on the short term, conditions of chronic hypoxia trigger 
mechanisms of remodelling that result in the development of irreversible PH.19 Uncontrolled 
proliferation and resistance to apoptosis of these cells have also been described as neoplastic-
like processes.20 Vascular remodelling is due to migration and proliferation of cells within all 
layers of the vessel wall, most prominently, however, of pulmonary artery SMCs and ECs, 
leading to a thickened and stiff vessel wall (Fig. 1).21 Additionally, narrowing of the arterial 
lumen can also be caused by coagulation of blood cells (microthrombosis).8 These processes 
influence the blood flow in the lungs, further raising the blood pressure and, during the 
progression of the disease, the increased workload of the heart results in right ventricular 
hypertrophy (RVH).22 To date, vascular remodelling is not satisfyingly addressed by 
treatment, as current treatment options only involve the vasoconstriction part.23 
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Figure 1. Pulmonary vascular remodelling in a rat model of PH. Compared to the control group (left), 
haematoxylin- and eosin-stained lung tissue from monocrotaline-treated rats shows hypertrophy of the artery 
within all cell layers (adventitia, media, and intima) due to vascular remodelling and aberrant vascular cell 
proliferation (right). Reproduced from Bai et al.24 
 
The development of modern therapies significantly improved the life expectancy of patients 
suffering from PH. So far, three different classes of drugs are clinically approved for the 
treatment of PH, which all are involved in a vasoactive dependent manner.22 Successfully 
employed strategies comprise of: 
(i) Prostanoids (e.g. epoprostenol (Flolan), a synthetic analogue of prostacyclin)25 
(ii) ET-1 receptor antagonist (e.g. Bosentan, Macitentan, and Ambrisentan)26 
(iii) Phosphodiesterase-5 (PDE5) inhibitors (e.g. Sildenafil or Tadalafil)27 
Prostacyclin, a prostanoid, is mainly produced by the endothelium and acts as a vasodilator, 
therefore widening the blood vessels via SMC relaxation. It has been shown that 
intravenously applied prostacyclin improved exercise capacity, haemodynamics, quality of 
life as well as survival of PH patients.28 Furthermore, ET-1 not only acts as a vasoconstrictor 
but also as a proliferative factor of SMC, therefore contributing to vascular remodelling in 
PH.29, 30 Blocking of ET-1 receptors by antagonists may counteract the pathophysiological 
condition seen in this disease. Moreover, inhibition of PDE-5 enzymes leads to intracellular 
cyclic guanosine monophosphate (cGMP) accumulation since PDE-5 is no longer able to 
degrade cGMP. As a result, the vasodilator NO will increase.31-33 A recent study has 
demonstrated that sildenafil given in combination with the blood hormone erythropoietin 
(Epo) showed an additive effect in survival and migration of hypoxic ECs.34 Additionally, the 
combination of sildenafil and Epo in vivo was able to effectively attenuate hypoxia-induced 
PH in mice.35 To summarize, all mentioned drugs above involve either a direct or indirect 
pathway leading to vasodilation, therefore possibly decreasing pulmonary vascular resistance. 
These agents, however, are often non-specific and face some serious drawbacks including 
1.1 Pulmonary Hypertension 
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short half-lives, higher dosing and frequency requirements, and several dose-related systemic 
side effects.36 
Despite the improvement in life quality, current therapies fail to cure PH. This is probably due 
to the fact that they only target the imbalance between vasoconstrictors and –dilators, whereas 
the process of vascular remodelling still continues. Therefore, extensive research has been 
conducted in the last years in order to understand the molecular mechanisms leading to 
vascular remodelling in PH. The ultimate goal is to reverse the process of pulmonary vascular 
remodelling, finally healing patients of their disease. In this context, dysregulated expression 
of bone morphogenetic protein receptor type II (BMPR2) is a pathogenetic hallmark and a 
common feature in the pathogenesis of PH, responsible for approximately 70% of hereditary 
PAH and 20% of idiopathic PAH.37 It has been shown in a novel pathway that cytokine 
interleukin-6 (IL-6) and the microRNA (miRNA) cluster miR-17/92 tightly control the 
expression of BMPR2 and therefore providing a novel mechanistic insight in the pathogenesis 
of pulmonary vascular remodelling.38 Long non-coding RNAs (lncRNA) are emerging as 
potential new players in the context of PH. For instance, metastasis-associated lung adeno-
carcinoma transcript 1 (MALAT1) is induced by hypoxia and depletion inhibited migration 
and proliferation of SMCs, potentially having implications for the pathogenetic understanding 
of the disease.39 Furthermore, one of the best characterized tumor suppressor genes is p5340 
and, in the context of PH, Jacquin et al. showed that p53 is found downregulated in the 
monocrotaline model of PH. Moreover, inactivation of p53 alone was sufficient to induce the 
development of experimental PH.41, 42 Another study demonstrated that exogenous NO has an 
inhibitory effect on smooth muscle cell proliferation via induction of p53 and p21.43 
To conclude, treatment options are available but new therapeutic options are highly needed, 
since the disease is still incurable. Patients reveal a progressive clinical deterioration and their 
prognosis is in most cases rather poor.22 On these grounds, already a minor improvement in 
the clinical outcome would mean an enhancement in the quality of life of concerned patients. 
 
1.2 AQUAPORINS 
Water as a universal solvent is the major component of all living cells and its transport (water 
influx and efflux) needs to be regulated. It was long assumed that simple diffusion alone 
accounts for all water movement through biological membranes. The problem, however, was 
that diffusion does not provide an explanation for the rapid water movement across plasma 
membranes of cells. Therefore, scientists believed that there must be a specialized protein 
1.2 Aquaporins 
5 
channel responsible for the fast water transport, which has been described physically despite a 
lack of molecular understanding.44 It was not until 1986 in Romania when Gheorghe Benga 
and colleagues discovered the first water channel protein in the membrane of erythrocytes.45, 
46 The same protein was purified by serendipity by Peter Agre group in 1987 in Baltimore.47 
Further studies indicated that the newly discovered protein was surprisingly abundant and 
could facilitate rapid and selective water movement in the direction of an osmotic gradient.48 
Hence, the temporary name channel-like integral membrane protein 28 kDa (CHIP28) was 
introduced firstly,49 and then replaced by the term aquaporin (AQP) which applies in this 
form until today.50 In contrast to simple diffusion alone, where water moves bidirectional in a 
low-capacity manner, the newly discovered AQPs have a high capacity, and great selectivity 
and permeability to water. Despite the two landmark publications from Benga group,45, 46 the 
Nobel Prize in Chemistry was awarded “for discoveries concerning channels in cell 
membranes” only to Peter Agre “for the discovery of water channel” in 2003, which aroused 
some controversies in the scientific community.51 
AQPs belong to a group of highly conserved membrane proteins that can be found 
ubiquitously in virtually all-living organisms.52 Their occurrence in the five kingdoms of life 
(animals, plants, fungi, eubacteria, and archaea) indicates a high preservation of the gene 
family over time. In mammals, 13 isoforms (AQP0-AQP12) were identified which are widely 
distributed in specific cell types in many organs and tissues including the lungs.53 With the 
completion of the human genome project in 2003, more members will not likely be identified.
 
Table 2. Mammalian aquaporins (AQP0-AQP12) and their permeability and tissue localization. Classical 
aquaporins (pale blue) are defined as channels highly selective for water, whereas aquaglyceroporins (blue) 
refer to the additional passage of glycerol and urea, along with water. Superaquaporins are depicted in dark blue 
(AQP11 & AQP12). Adopted from Kreida et al. & King et al.54, 55 
 
Aquaporin Selectivity Localization 
AQP0 Water Eye lens 
AQP1 Water Red blood cells, kidney, blood vessel, lung, brain, eye 
AQP2 Water Kidney (collecting duct) 
AQP3 Water, glycerol, urea Kidney, skin, intestine, eye, lung 
AQP4 Water Brain, kidney, muscle, lung, gastro-intestinal tract, eye, airways 
AQP5 Water Lung, airways, cornea, pancreas, salivary and sweat glands 
AQP6 Water Kidney 
AQP7 Water, glycerol, urea Adipose tissue, kidney, liver, testis, heart muscle 
AQP8 Water Gastro-intestinal tract, kidney, liver, testis 
AQP9 Water, glycerol, urea Liver, brain, testis, leukocytes 
AQP10 Water, glycerol, urea Small intestines 
AQP11 Water Liver, testis, kidney 
AQP12 Unknown Pancreas 
1.2 Aquaporins 
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Each type differs mainly in its tissue distribution and permeability characteristics and can 
therefore be divided into three subsets based on the primary sequence: (i) classical 
aquaporins, considered to be water selective, (ii) aquaglyceroporins, permeable to glycerol 
and other small solutes (e.g. urea) in addition to water, and (iii) superaquaporins, whose 
specific function, apart from water transport, remains to be clarified (Table 2).56, 57 
AQPs belong to the family of transmembrane proteins, more precisely to small integral 
membrane proteins, therefore permanently attached to the plasma membrane. The different 
AQPs subsets deviate in their peptide sequence, thus showing different pore sizes. The 
monomeric units of AQP1 are about 28 kDa, depending on glycosylation and 
phosphorylation, and appears as a homotetramer where each monomer consists of six 
membrane-spanning α-helices (M1, M2, M4-M6 and M8), two half-helices (M3 and M7) and 
five connecting loops (a-e), forming an hourglass-shaped structure, where both the amino and 
carboxyl terminus are located in the cytoplasm (Fig. 2a).52, 58-60 Two structures within the 
channel account for the selective passage of water: (i) the highly conserved three residue 
motif asparagine-proline-alanine (NPA) in loops b and e and (ii) the so called 
aromatic/arginine (ar/R) constriction region (Fig. 2b). The former is responsible that upon  
 
  
Figure 2. Membrane topology of aquaporin 1 (AQP1). a Schematic of the AQP1 monomer consisting of six 
transmembrane α-helices (M1, M2, M4-M6 & M8), two half-helices (M3 & M7) and five connecting loops (a-
e). b Extracellular vestibule of AQP1 with conserved NPA motif (orange) and ar/R constriction region (green) 
accounting for proton exclusion and selective transit of water molecules. Reproduced from Verkman et al.60 
 
entering, a rotation of water molecules occurs caused by hydrogen bonds between the oxygen 
atom of the water molecule and the asparagines in the two NPA motifs, a possible cause to 
prevent protons from crossing the pores.61, 62 The latter ar/R constriction site refers to the 
narrow pore region, formed by arginine, histidine, phenylalanine, and cysteine.63 It has been 
shown that cysteine is the blockage site of AQP1 by mercury chloride (HgCl2, see further 
below), which is thought to sterically occlude the water pore.64, 65 The two amino acids 
arginine and histidine provide positive charges to further repel proton passage, while 
a b 
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permitting rapid transport of single water molecules through the narrow pore.66 In conclusion, 
both mechanisms exhibit electrostatic barriers accounting for proton exclusion and the 
selective transit of water molecules. 
AQPs can be found throughout the body and are differentially expressed in organs and tissues 
involved in fluid absorption or secretion, such as epithelial cells, but also in non-fluid 
transporting tissues like brain, skin, fat, and liver (Fig. 3). It has been shown that AQPs are 
additionally involved in various physiological functions including trans-epithelial fluid 
transport, cell migration (e.g. wound healing, tumour metastasis, and glial scar formation), 
cell proliferation, angiogenesis, brain water regulation, adipocyte metabolism, and 
neuroexcitation.60 These processes are, probably by the action of AQPs, of major importance 
for the physiological adaption to hypoxia as well as in the pathophysiology of cancer and 
hypoxia-related diseases.67-69  
  
 
 
Figure 3. Tissue distribution of mammalian aquaporins (AQPs). AQPs are widely expressed in the body, 
particularly in cell types involved in fluid transport, such as epithelial cells in several organs, as well as in some 
cell types that do not have an obvious role in fluid transport, such as adipocytes. Of importance, AQP1 is 
expressed in the endothelium and in smooth muscle cells (not shown). Reproduced from Verkman et al.60 
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A steadily growing number of studies emphasize that AQPs seem to be strongly involved in 
stress-induced tissue transformation processes. Recently, it was suggested that hypoxia 
modulates AQP1 expression in different organs, e.g. mouse lungs.70 Moreover, in rat 
pulmonary artery smooth muscle cells, hypoxia selectively increased AQP1 protein levels 
and, in turn, migration of these cells. Silencing of AQP1 via siRNA prevented the hypoxia-
induced migration.71 Furthermore, a study investigated the role of the C-terminal tail of AQP1 
on migration and proliferation, because the exact mechanism by which AQP1 facilitates these 
two processes was unknown.72 In this setting, the C-terminus was required since its deletion 
in AQP1 overexpressing rat smooth muscle cells abolished the effect on both migration and 
proliferation. The authors concluded that the possible AQP1-mediated mechanisms include 
association of factors or proteins with the C-terminal tail, however, without offering an 
explanation how AQP1 executes its function in this context. A proposed model of AQP1-
mediated migration was prompted by Saadoun et al., where AQP1 expression polarizes to the 
leading edge of lamellipodia extension, facilitating water influx and cell migration, therefore 
hypothesizing a possible connection between AQP1 and the cytoskeleton.73 
In addition, enhanced p53 expression levels were found after silencing of AQP3 with shRNA 
in a non-small cell lung cancer (NSCLC) model, which was accompanied with suppressed 
tumour proliferation.74 AQP3 knockdown reduced cellular glycerol content (AQP3 is an 
aquaglyceroporin) and mitochondrial ATP formation, which, together with reduced 
expression of the proliferation marker proliferating cell nuclear antigen (PCNA), might 
contribute to the inhibitive effect on tumour proliferation. Of note, the importance of AQP1 
for the vascular smooth muscle phenotype was highlighted in a study by Al Ghouleh et al. 
demonstrating that reactive oxygen species are channelled via AQP1 resulting in hypertrophy, 
however, without affecting proliferation.75 Moreover, microarray data further revealed 
alterations in several proliferation-regulating genes suggesting that AQP1 modifies the 
expression of key cell cycle proteins.76 All these data suggest a possible link between the 
excessive vascular remodelling observed in patients with PH and both expression and 
function of AQP1. 
Surprisingly, there is a lack of verified pharmacological inhibitors for AQPs, but studies of 
the phenotype of AQP-knockout mice have provided most of the information on AQP 
physiology. Compelling evidence from studies using AQP-knockout mice and from humans 
with AQPs loss-of-function mutations suggest AQPs as drug targets, having broad clinical 
indications in nephrology, neurology, oncology, and ophthalmology. The identification of 
AQP modulators, however, has turned out to be unexpectedly challenging and the poor
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drugability of AQPs may be, among others, due to the small size of the functional AQP 
monomer and its very small pore diameter, which prevents the access of small molecules.60 
There has been extensive research on the identification of AQP inhibitors, but no study found 
any suitable candidate, even when tested 1’000’000 compounds in a virtual screen.77 There is 
one exception: HgCl2 has been widely used as an inhibitor of AQP1 and is thought to 
sterically occlude the water pore.64, 65 However, HgCl2 is a nonspecific inhibitor and 
potentially very toxic if given in high doses, therefore unsuitable for in vivo use. To overcome 
the poor drugability of the AQP1 protein, inhibition of AQP1 mRNA by antisense 
oligonucleotides (ASO) strategy could offer an attractive alternative. The so-called GapmeRs 
are short single-stranded antisense oligonucleotides modified with locked nucleic acids 
(LNA) in the flanking regions and DNA in a central gap (hence the name) to ensure enhanced 
stability and high affinity and were proven to repress gene expression in mice and non-human 
primates.78 Application of GapmeRs directed against AQP1, for instance, would result in 
RNase H-dependent degradation of complementary AQP1 RNA, both in vitro and in vivo. 
GapmeR inhibitors show high binding-efficacy, stability and a good bio-distribution whereas 
activation of the innate immune system (a common unwanted effect for RNA interference 
approaches) is unlikely. This makes GapmeRs an attractive therapeutic tool that might be very 
well tolerated by the recipient. The use of these novel antisense oligonucleotides could be 
limited by non-specific binding to proteins and off-target effects such as hepatotoxicity.79 
Consequently, researchers are very interested in finding new nontoxic alternatives being 
selective for AQPs, having implications in clinical therapies and the treatment of human 
diseases.80  
 
1.3 OBJECTIVES 
On the grounds of the above-mentioned introduction, the aim of my PhD thesis was to 
examine the involvement of AQP1 as a potential key player in the development of hypoxia-
induced PH, whose pathogenesis is characterized by vascular remodelling and 
vasoconstriction. To the best of our knowledge, however, little is known about the interaction 
between AQP1, hypoxia, and PH and the role of AQP1 in the pathobiology of vascular 
remodelling in PH has not been directly addressed so far. Although the mechanism of action 
remains poorly understood, it has been shown in several studies that upon hypoxia, the 
expression of AQP1 is increased.70, 71 As AQP1 is the best described of all AQPs and 
additionally expressed in pulmonary vascular SMCs and ECs, the present study was designed
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to investigate the expression and function of AQP1 in vitro in human vascular cells derived 
from pulmonary arteries and in vivo in the mouse model of hypoxia-induced PH. In detail, the 
functional consequence of altered AQP1 expression in human vascular cells (human 
pulmonary vascular smooth muscle (HPASMC) and endothelial cells (HPAEC), respectively) 
was assessed with an emphasis on migration, proliferation and resistance to apoptosis. 
Manipulation of AQP1 expression was achieved using GapmeRs for silencing experiments 
and an overexpression vector to induce AQP1 levels. The physiological consequences of 
AQP1 depletion via intraperitoneal (i.p.) GapmeR injections on haemodynamics were further 
addressed in vivo by employing the hypoxia-induced mouse model of PH. Elaborately, the 
focus was set on measuring right ventricular pressure (RVP) and RVH. In the following 
chapter 2 ‘Aquaporin 1 controls the functional phenotype of pulmonary smooth muscle cells 
in hypoxia-induced pulmonary hypertension’ of this PhD thesis, the data on the role of AQP1 
function and expression in the context of hypoxia-induced PH are presented. 
 
Thus, the following working hypotheses have been defined: 
 
• Hypoxia can modulate the expression of AQP1, which is important for the progression 
and pathogenesis of PH. 
• AQP1 contributes to hypoxia-induced tissue remodelling. 
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2.1 ABSTRACT 
Vascular remodelling in hypoxia-induced pulmonary hypertension (PH) is driven by 
excessive proliferation and migration of endothelial and smooth muscle cells. The expression 
of aquaporin 1 (AQP1), an integral membrane water channel protein involved in the control 
of these processes, is tightly regulated by oxygen levels. The role of AQP1 in the 
pathogenesis of PH, however, has not been directly addressed so far. This study was designed 
to characterize expression and function of AQP1 in pulmonary vascular cells from human 
arteries and in the mouse model of hypoxia-induced PH. Exposure of human pulmonary 
vascular cells to hypoxia significantly induced the expression of AQP1. Similarly, levels of 
AQP1 were found to be upregulated in lungs of mice with hypoxia-induced PH. The 
functional role of AQP1 was further tested in human pulmonary artery smooth muscle cells 
demonstrating that depletion of AQP1 reduced proliferation, the migratory potential, and, 
conversely, increased apoptosis of these cells. This effect was associated with higher 
expression of the tumour suppressor gene p53. Using the mouse model of hypoxia-induced 
PH, application of GapmeR inhibitors targeting AQP1 abated the hypoxia-induced 
upregulation of AQP1 and, of note, reversed PH by decreasing both right ventricular pressure 
and hypertrophy back to the levels of control mice. Our data suggest an important functional 
role of AQP1 in the pathobiology of hypoxia-induced PH. These results offer novel insights 
in our pathogenetic understanding of the disease and propose AQP1 as potential therapeutic in 
vivo target. 
 
2.2 INTRODUCTION 
Pulmonary hypertension (PH) is the pathophysiological consequence of several diseases and 
is, in many cases, triggered or aggravated by hypoxia [26, 28, 30]. The pulmonary vasculature 
of PH patients is characterized by vasoconstriction, microthrombotic events, and excessive 
remodelling of the small pulmonary arteries [9, 24]. Whereas acute hypoxia increases 
pulmonary pressure by calcium-mediated vasoconstriction of pulmonary vascular smooth 
muscle cells on the short term, conditions of chronic hypoxia, including many parenchymal 
lung diseases, trigger mechanisms of remodelling that result in the development of 
irreversible pulmonary hypertension [37]. Vascular remodelling is due to migration and 
proliferation of cells within all layers of the vessel wall, most prominently, however, of 
pulmonary artery smooth muscle and endothelial cells [20]. Uncontrolled proliferation and 
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resistance to apoptosis of these cells have also been described as neoplastic-like processes 
[29]. To date, vascular remodelling is not satisfyingly addressed by treatment [7].  
The mammalian aquaporins (AQPs) are a class of water channels that regulate the rapid water 
movement across the plasma membrane in response to an osmotic gradient [18]. The AQP 
family consists of 13 different subsets (AQP0-12) so far which are expressed in multiple 
organs including the lungs. AQPs are involved in various physiological processes such as 
trans-epithelial fluid transport, cell migration, cell proliferation, and angiogenesis [35]. These 
processes are, probably by the action of AQPs, of major importance for the physiological 
adaption to hypoxia as well as in the pathophysiology of cancer [34] and hypoxia-related 
diseases [27].  
A steadily growing number of studies emphasize that AQPs seem to be strongly involved in 
stress-induced tissue transformation processes. Recently, it was suggested that hypoxia 
modulates AQP1 expression in different organs, e.g. mouse lungs [1]. Moreover, in rat 
pulmonary artery smooth muscle cells, hypoxia selectively increased AQP1 protein levels 
and, in turn, migration of these cells [14]. These data suggest a possible link between the 
excessive vascular remodelling observed in patients with PH and both expression and 
function of AQP1.  
However, the role of AQP1 in the pathobiology of vascular remodelling in PH has not been 
directly addressed so far. The present study was designed to investigate the expression and 
function of AQP1 in human vascular cells derived from pulmonary arteries and in the mouse 
model of hypoxia-induced PH. In detail, the functional consequence of altered AQP1 
expression in human vascular cells was assessed with an emphasis on migration, proliferation 
and resistance to apoptosis. The physiological consequences of AQP1 depletion on 
haemodynamics were further addressed in vivo by employing the hypoxia-induced mouse 
model of PH. 
 
2.3 METHODS 
Animal experiments 
 
Male mice (C57BL/6, aged 12 weeks) were obtained from Charles River (Sulzfeld, Germany) 
and used for the hypoxia-induced PH mouse model as previously described in our 
publications [3, 4]. Briefly, the animals were randomized into a normoxic control group (n = 
8, room air, 21% O2) and a hypoxic group (n = 8, 10% O2). Normobaric hypoxic condition 
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was provided in a sealed glove-chamber connected to a gas mixer (Coy Laboratory Products, 
Grass Lake, MI, USA). Mice were assessed daily for activity and wellbeing. All animals had 
access to standard diet and tap water ad libitum. At day 35, after 5 weeks of hypoxic expo-
sure, mice were anaesthetized (induction, 5% isoflurane; maintenance, 1.5–2% isoflurane and 
100% O2) and systemic arterial pressure (SAP) was measured in the isolated femoral artery. 
Next, right ventricular pressure (RVP) was evaluated as an endpoint measurement of PH, 
performed by right heart catheterization as previously described [10]. Mice were subsequently 
euthanized by cervical dislocation and lungs were collected for further analysis. 
For treatment experiments, an additional mouse experiment was employed. Mice were 
divided into treatment and control groups (four groups of n = 8 each). After 3 weeks of 
hypoxic exposure (10% O2), the hypoxic mice were randomly assigned to three different 
groups to be further kept untreated or treated every 4 days by intraperitoneal (i.p.) injections 
with antisense oligonucleotides (GapmeRs) directed against AQP1 or GapmeR scrambled 
negative control (10 mg/kg solved in sterile 0.9% NaCl). GapmeRs are short oligonucleotides 
modified with locked nucleic acids (LNA) in the flanking regions and DNA in a central gap 
(hence the name GapmeR). Application of GapmeR AQP1 results in RNase H-dependent 
degradation of complementary AQP1 RNA.  
One mouse (hypoxic GapmeR negative control) died during the course of the experiment. 
Two weeks later, mice were analysed for RVP. The RVP of two hypoxic GapmeR AQP1 
mice could not be measured, since these mice died during right heart catheterization. 
Afterwards, animals were euthanized and lungs were harvested. To assess right ventricular 
hypertrophy, the ratio between right ventricular and left ventricular diameter including 
interventricular septum [RV/(LV+S)] was calculated based on the average of three linear 
diameter measurements across each heart section. All animal experiments were approved by 
the Cantonal Veterinary Office Zurich (approval numbers 151/2012 and 212/2014) and 
performed according to the guidelines from Directive 2010/63/EU of the European 
Parliament. 
 
Cell culture 
 
Human pulmonary artery smooth muscle (HPASMC) (ScienCell, Carlsbad, CA, USA; donor 
#1 and #2) and human pulmonary artery endothelial cells (HPAEC) (ScienCell, Carlsbad, CA, 
USA; donor #1, and PromoCell, Heidelberg, Germany; donor #2) derived from two healthy 
donors were expanded in cultures according to the manufacturer’s instructions. Cells were 
incubated in a humidified atmosphere at 37 °C and 5% CO2. In all experiments, one batch of 
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cells with passage number between two and eight was used. Cells were seeded and allowed to 
settle for at least 12 h before being transfected or exposed to hypoxia. Hypoxic experiments 
(1% O2) were carried out over different time points (e.g. functional assays for 48 h) in an O2 
adjustable incubator (Binder, Tutlingen, Germany) maintained at 37 °C with 5% CO2.  
 
Transient transfection of primary cultured cells 
 
For manipulation of endogenous levels of AQP1, HPASMC were transfected with GapmeR 
targeting AQP1 or GapmeR negative control (25 nmol/L) using Lipofectamine 2000 
transfection reagent (Life Technologies, Zug, Switzerland) according to the manufacturer’s 
protocol. Cell culture grade GapmeR inhibitors were obtained from Exiqon (Vedbaek, 
Denmark) and their sequences are listed in Supplementary Table 1. Following an incubation 
period of 24 or 48 h, cells were either harvested for gene expression analysis or prepared for 
functional assays. 
 
Plasmid construction and overexpression 
 
The conventional PCR was used to amplify the coding sequence of AQP1 (809 bp) out of 
cDNA from HPASMC. The obtained PCR product was digested with HindIII and XhoI and 
subsequently cloned into pcDNA 3.1(+) vector (Invitrogen, Basel, Switzerland). Successful 
insertion of AQP1 was confirmed by Sanger sequencing (Microsynth, Balgach, Switzerland). 
Primers used for cloning are provided in Supplementary Table 2. To overexpress AQP1, 
HPASMC were transfected either with 0.25 µg pcDNA_AQP1 or its corresponding empty 
vector, which served as a negative control, using electroporation technique (Amaxa 
Nucleofactor kit, Lonza, Basel, Switzerland). Subsequently, after 48 h, cells were harvested 
and gene overexpression was analysed by western blotting or cells were prepared for 
migration and proliferation assays.  
 
Quantitative real-time PCR (qPCR) analysis 
 
Total RNA of cultured cells or murine lung tissue samples were purified using the Quick-
RNA MiniPrep kit (Zymo Research, Freiburg im Breisgau, Germany) or the miRNeasy Mini 
kit (Qiagen, Hombrechtikon, Switzerland), respectively. Quality of isolated RNA was 
assessed by spectrophotometric analysis (Nanodrop, Wilmington, DE, USA). Isolated RNA 
was reverse-transcribed using random hexamers and GoScript reverse transcriptase (both 
from Promega, Dübendorf, Switzerland). Quantification of specific gene transcripts was 
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performed by SYBR Green qPCR (Applied Biosystem StepOnePlus system, Life 
Technologies). To avoid amplification of genomic DNA, primers were designed to span an 
exon–exon junction. Sequences of primers used for gene expression analysis are listed in 
Supplementary Table 2. Specific amplification was verified performing melt curve analysis. 
Obtained expression levels of genes of interest were normalized to the expression of β-actin. 
Differential gene expression was calculated using the threshold cycle (Ct) method [25].  
 
Western blotting 
 
For protein extraction, harvested cells and murine lung tissue samples were lysed or 
homogenized using sample loading buffer (62.5 mM Tris–HCl, pH 6.8, 2% sodium dodecyl 
sulphate (SDS), 10% glycerol, 5 mM β-mercaptoethanol, bromophenol blue). Whole-cell 
lysates (30 µg of protein) were separated by 12% sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) and proteins were transferred by electroblotting to a 
nitrocellulose membrane (Whatman, GE Healthcare Life Sciences, Little Chalfont, UK). 
Membranes were blocked with 5% dry milk in Tris-buffered saline containing 0.1% Tween 
20 (TBS-T) and incubated over night at 4 °C with the following primary antibodies: anti-
AQP1 (rabbit monoclonal, #ab168387, Abcam, Cambridge, UK), anti-hypoxia-inducible 
factor 1 alpha (HIF-1α) (rabbit polyclonal, #NB100-479, Novus Biologicals, Littleton, CO, 
USA), anti-p53 (mouse monoclonal, #sc-126, Santa Cruz Biotechnology, Dallas, TX, USA), 
and anti-β-actin (mouse monoclonal, #A2228, Sigma-Aldrich, Buchs SG, Switzerland), 
respectively. β-actin was used as a housekeeping protein for normalization. Bands were 
detected using species-specific secondary anti-bodies conjugated to horseradish peroxidase 
(Dako Agilent Technologies, Glostrup, Denmark). Calculation of the expression of proteins 
was performed using Adobe Photoshop CS5.1 software (Adobe Systems Incorporated, San 
Jose, CA, USA) via pixel quantification of the electronic image.  
 
Migration assay 
 
Migration of HPASMC was addressed according to a modified in vitro wound-healing assay. 
Briefly, 30’000 cells were seeded on each side of an Ibidi culture insert µ-dish (Ibidi, Munich, 
Germany) for live cell analysis and transfected with GapmeR targeting AQP1 or scrambled 
negative control as described above. In addition, HPASMC were transfected with AQP1 
overexpressing vector (pcDNA_AQP1) as stated above. Cells were allowed to grow to 
confluence for 24 h and afterwards, inserts were removed with sterile tweezers to create a 
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cell-free gap of approximately 500 µm width. The closure of the wound by migrating cells 
was quantitatively assessed at various time points after being photographed at 4x 
magnification under an inverted microscope (Olympus CKX41) as previously described [21]. 
The area of the initial wound was compared to the area of the healing wound at three different 
time points (3, 5, and 7 h).  
 
Proliferation and apoptosis assay 
 
To assess the proliferation rate, HPASMC were seeded in a 96-well plate at a density of 5000 
cells per well and transfected with GapmeR targeting AQP1 or scrambled negative control as 
described above. For AQP1 overexpression, 10’000 cells were used and transfected either 
with pcDNA_AQP1 or its corresponding empty vector as mentioned above. After 24 h, 5-
bromo-2-deoxyuridine (BrdU) was added to each well and cells were incubated for an 
additional 24 h. Incorporation of BrdU was detected using the colorimetric BrdU assay from 
Roche (Roche Diagnostics, Mannheim, Germany). To assess apoptosis, HPASMC were 
seeded in a 96-well plate at a density of 10’000 cells per well and transfected with GapmeR 
targeting AQP1 or scrambled negative control. After 48 h, apoptosis was evaluated in 
unstimulated cells (spontaneous apoptosis) by measuring the activity of caspase 3 and 7 
(Caspase-Glo 3/7 assay, Promega, Dübendorf, Switzerland) according to the manufacturer’s 
protocol. 
 
Statistics 
 
All data are presented as mean ± standard deviation (SD). Parametric or non-parametric 
distribution of data was determined using the Kolmogorov–Smirnov test. Data comparison 
was performed using independent Student’s t test as well as Pearson’s correlation for 
parametric samples. For comparing more than two sample groups, the one-way analysis of 
variance (ANOVA) with Tukey post hoc test for parametric samples and the Kruskal–Wallis 
test with Dunn’s post hoc test for non-parametric samples was used. Paired Student’s t test or 
repeated-measures ANOVA was used with Tukey post hoc test to analyse functional assays 
and AQP1 gene expression levels (paired observations of the same subject). In all statistical 
analyses, two-sided tests were applied. Values of p < 0.05 were considered to be statistically 
significant (*p < 0.05, **p < 0.01, ***p < 0.001). The n number indicates independent 
experiments. All statistical calculations were performed using the software package GraphPad 
Prism Version 5.0a (GraphPad Software, San Diego, CA, USA). 
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2.4 RESULTS 
AQP1 expression is increased in the mouse model of hypoxia-induced PH 
 
The regulation of AQP1 by hypoxia was characterized in lung samples of the mouse model of 
hypoxia-induced PH. As presented in Fig. 1a, mice exposed to chronic hypoxia showed a 
significant elevation in RVP compared to normoxic control mice (in mmHg: hypoxic mice 
45.45 ± 3.63 vs. normoxic mice 30.83 ± 2.60, p < 0.001) indicating a successful in vivo 
application of the hypoxia-induced PH model. In lung tissue obtained from these mice, 
mRNA levels of AQP1 were significantly upregulated after hypoxia compared to normoxic 
control animals (by 1.31 ± 0.14 fold change, p < 0.01; Fig. 1b). These data were confirmed on 
protein level by Western blotting. AQP1 protein levels were significantly increased after 
exposure to chronic hypoxia (by 1.92 ± 0.70 fold change, p < 0.01; Fig. 1c). Since the levels 
of AQP1 were significantly upregulated under hypoxic conditions, a correlation analysis was 
performed showing a significant positive correlation of AQP1 protein levels with the RVP of 
experimental animals (r = 0.636, p < 0.01; Fig. 1d). 
 
 
Figure 1. AQP1 expression is increased in the mouse model of hypoxia-induced PH. Mice were exposed to 
10% O2 for 5 weeks or kept under normoxia as controls. (a) Right ventricular pressure (RVP, in mmHg) 
measured by right heart catheterization in normoxic (Nx) and hypoxic (Hx) mice. Effect of hypoxia on mRNA 
(b) and protein (c) levels of AQP1 from lung homogenates measured by qPCR and western blot compared to 
normoxic animals. A representative blot is provided (30 µg). (d) Correlation analysis of AQP1 protein 
expression with RVP of the corresponding mouse. n = 8 mice per group. Statistical analysis by unpaired 
Student’s t test (a–c) and Pearson’s correlation (d) (**p < 0.01, ***p < 0.001). 
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AQP1 is expressed in human pulmonary vascular cells 
 
In a next step, the basal expression levels of AQP1 in HPASMC and HPAEC, the two main 
cell types being involved in the process of vascular remodelling, were investigated. Both cell 
types express AQP1 on mRNA as well as protein levels. An increased mRNA expression of 
AQP1 in HPAEC was observed compared to HPASMC (e.g. ΔCt of 8.74 ± 2.01 in HPAEC 
donor #1 vs. ΔCt of 15.09 ± 0.56 in HPASMC donor #2, p < 0.05; Fig. 2a). On protein level, 
there was no significant difference in the expression levels of AQP1 between the two donors 
of pulmonary vascular cell types (Fig. 2b).  
 
 
Figure 2. AQP1 is expressed in human pulmonary vascular cells. Human pulmonary artery endothelial 
(HPAEC) and smooth muscle cells (HPASMC) express AQP1 on mRNA (a) as well as protein (b) level. A 
representative western blot is shown (30 µg). n = 4–5 per group. Statistical analysis by Kruskal–Wallis test with 
Dunn’s post hoc test (a) and one-way ANOVA with Tukey post hoc test (b) (*p < 0.05, **p < 0.01). 
 
Exposure to hypoxia drives the expression of AQP1 in human pulmonary vascular cells 
 
To further investigate the role of AQP1 in hypoxia-induced PH, pulmonary cells were 
exposed to hypoxia over different time points (1% O2 for 2–72 h). As indicated in Fig. 3a, 
HPAEC showed the highest peak in AQP1 mRNA expression after 8 h of hypoxic exposure 
(by 1.63 ± 1.12 fold change, not significant; donor #1), whereas long-term hypoxia (24–72 h) 
decreased mRNA levels with a significant reduction after 72 h in donor #2 (reduction to 0.07 
± 0.04, p < 0.05). mRNA levels of AQP1 in HPASMC (donor #1) were significantly 
upregulated after 8 h (by 2.18 ± 0.80 fold change, p < 0.05), 24 h (by 2.87 ± 0.89 fold change, 
p < 0.001), and 48 h (by 2.10 ± 0.34 fold change, p < 0.05) of hypoxic exposure. In donor #2, 
however, hypoxia did not change AQP1 mRNA levels (Fig. 3b). Protein expression of AQP1 
in HPAEC was only found significant after 72 h of hypoxia in donor #2 (by 1.88 ± 0.49 fold 
change, p < 0.01; Fig. 3c). In contrast, long-term hypoxia increased AQP1 protein levels in 
HPASMC, with a significant elevation after 48 h (by 1.80 ± 0.36 fold change, p < 0.05; donor 
#1) and, e.g. 72 h (by 2.18 ± 0.15 fold change, p < 0.001; donor #2) of hypoxic exposure (Fig. 
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3d). Successful application of the hypoxic condition is indicated by representative Western 
blots of HIF-1α stabilization (Fig. 3c, d) as well as marked increase in mRNA levels of the 
HIF-1α inducible gene VEGFα (positive control, data not shown). 
 
 
Figure 3. Exposure to hypoxia drives the expression of AQP1 in human pulmonary vascular cells. Two 
different donors for both vascular cell types were exposed to hypoxia (1% O2 for 2–72 h). (a, b) Effect of 
hypoxia on mRNA levels in HPAEC and HPASMC. (c, d) Effect of hypoxia on protein levels in HPAEC and 
HPASMC. Representative Western blots are provided (30 µg). Immunodetection of HIF-1α was used to confirm 
successful application of hypoxia. n = 5–6 per group. Statistical analysis by Kruskal–Wallis test with Dunn’s 
post hoc test (a, c) and one-way ANOVA with Tukey post hoc test (b, d) (*p < 0.05, **p < 0.01, ***p < 0.001). 
 
Silencing of AQP1 affects the phenotype of human pulmonary artery smooth muscle 
cells 
 
Since there was no difference in the amount of AQP1 protein expression in HPASMC and 
HPAEC (Fig. 2b) and the fact that HPASMC responded best to the hypoxic condition (Fig. 3), 
we focused on the latter cell type to continue with and to perform the following experiments 
and functional assays. 
To evaluate the physiological role of AQP1 in the process of migration, proliferation, and
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apoptosis in HPASMC, the endogenous expression of AQP1 was silenced by transfection 
with GapmeRs. As measured by qPCR, transfection of HPASMC with GapmeR targeting 
AQP1 significantly reduced the expression of AQP1 compared to non-transfected and 
negative control transfected cells in donor #1 (by 0.42 ± 0.19 fold change, p < 0.01; Fig. 4a). 
In addition, these data were confirmed on protein level by Western blots demonstrating a 
significant decrease of AQP1 protein levels in donor #1 (by 0.66 ± 0.13 fold change, p < 0.01; 
Fig. 4b). 
In terms of migration, as shown in Fig. 4c, silencing of AQP1 in HPASMC significantly 
lowered the rate of healing in wound-healing assays (e.g. after 7 h of migration: GapmeR 
negative control 39.38% ± 5.00 vs. GapmeR AQP1 28.88% ± 7.86, p < 0.001; donor #1). 
Representative pictures of migrated HPASMC are provided in Supplementary Figure 1. 
Likewise, as assessed by BrdU incorporation assay, transfection with GapmeR AQP1 resulted 
in a significantly reduced proliferation rate of HPASMC (donor #1) compared to non-
transfected and GapmeR negative control transfected cells (in absorbance at 450 nm: GapmeR 
negative control 1.76 ± 0.17 vs. GapmeR AQP1 1.45 ± 0.24, p < 0.01; Fig. 4d). Conversely, 
HPASMC depleted of AQP1 showed significantly higher caspase 3/7 activity compared to 
both non-transfected and negative control transfected cells (in relative luminescence units: 
GapmeR negative control 4138 ± 1106 vs. GapmeR AQP1 5558 ± 1630, p < 0.01; Fig. 4e) 
indicating a higher degree of spontaneous apoptosis when AQP1 is silenced. All results were 
confirmed using a second donor of HPASMC. 
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Figure 4. Silencing of AQP1 affects the phenotype of HPASMC. Consequence of GapmeR transfection 
against AQP1 (25 nmol/L) on both mRNA (a) and protein (b) levels in two donors of HPASMC compared to 
non-transfected and GapmeR negative control transfected cells. Representative western blots are shown (30 µg). 
Wound-healing (c) and BrdU incorporation (d) assays were performed assessing migration (rate of healing in %) 
and proliferation (absorbance at 450 nm) of HPASMC after GapmeR AQP1 transfection. (e) Effect of AQP1 
depletion in HPASMC on apoptosis as assessed by a luminescent assay that measures caspase-3 and -7 activities 
simultaneously (relative luminescence units). n = 5–6 per group. Statistical analysis by repeated-measures 
ANOVA with Tukey post hoc test (a, b top, c–e top) and paired Student’s t test (a, b, d, e bottom) (*p < 0.05, 
**p < 0.01, ***p < 0.001). 
 
Silencing of AQP1 affects the phenotype of hypoxic human pulmonary artery smooth 
muscle cells 
 
To investigate the function of AQP1 under hypoxic conditions, HPASMC were transfected 
with GapmeR AQP1 and exposed to hypoxia, and, 48 h later, their functional profile was 
assessed. As indicated in Fig. 5a, inhibiting AQP1 resulted in significantly less hypoxic 
migration of HPASMC compared to non-transfected as well as negative control transfected 
cells (e.g. donor #1: rate of healing in % after 7 h: Hx GapmeR negative control 31.88% ± 
4.06 vs. Hx GapmeR AQP1 10.45% ± 4.36, p < 0.001). Representative pictures of migrated 
HPASMC are provided in Supplementary Figure 2. In addition, hypoxic HPASMC depleted 
of AQP1 showed significantly lower proliferation compared to control transfected cells
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(donor #1 in absorbance at 450 nm: Hx GapmeR negative control 0.57 ± 0.21 vs. Hx GapmeR 
AQP1 0.17 ± 0.04, p < 0.01; Fig. 5b). Of note, GapmeR neg. control transfected cells had 
significantly less proliferation rates compared to hypoxic non-transfected control cells. 
Moreover, in terms of apoptosis, HPASMC transfected with GapmeR AQP1 and exposed to 
hypoxia showed significantly higher caspase 3/7 activity in comparison to both control setups 
(donor #1 in relative luminescence units: e.g. Hx GapmeR negative control 1415 ± 181 vs. Hx 
GapmeR AQP1 8538 ± 767, p < 0.001; Fig. 5c). Using a second donor of HPASMC, all 
results were confirmed. In summary, our experiments highlight the importance of AQP1 in 
the regulation of apoptosis, migration, and proliferation of HPASMC in normoxic as well as 
hypoxic conditions.  
 
 
Figure 5. Silencing of AQP1 affects the phenotype of hypoxic HPASMC. Cells were transfected with 
GapmeR AQP1 (25 nmol/L), exposed to hypoxia and, 48 h later, their functional profile was assessed. Migratory 
(a) (rate of wound healing in %) and proliferative (b) (absorbance at 450 nm) responses of HPASMC after 
depletion of AQP1 via GapmeR compared to control cells. (c) Apoptosis of HPASMC transfected with GapmeR 
targeting AQP1 as evaluated by a luminescent assay that measures caspase-3 and -7 activities simultaneously 
(relative luminescence units). n = 5–6 per group. Statistical analysis by repeated-measures ANOVA with Tukey 
post hoc test (a–c) (*p < 0.05, **p < 0.01, ***p < 0.001). 
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AQP1 controls the expression of p53 in human pulmonary artery smooth muscle cells 
 
To elucidate the molecular mechanism of AQP1 depletion in HPASMC, tumour suppressor 
and cell cycle inhibitor genes that have previously been implicated in the pathogenesis of PH 
were characterized in HPASMC transfected with GapmeR targeting AQP1. In detail, the 
mRNA levels of p53, BCL2, CDKN1A, and CDKN2A were measured by qPCR 
demonstrating a significant upregulation of p53 after transfection with GapmeR targeting 
AQP1 (by 1.43 ± 0.15 fold change for donor #1 and by 3.18 ± 0.54 fold change for donor #2, 
p < 0.001; Fig. 6a), whereas no significant changes could be observed when the expression of 
the other genes was assessed (data not shown). Along that line, protein levels of p53 were 
significantly increased in both donor #1 by 2.97 ± 0.77 fold change (p < 0.001) and donor #2 
by 5.18 ± 3.18 fold change (p < 0.05; Fig. 6b) when AQP1 was depleted in HPASMC 
compared to negative control transfected cells. Of interest, the expression of p53 was 
decreased in both HPASMC donors exposed to long-term hypoxia (e.g. 72 h of hypoxia: 0.71 
± 0.11 fold change for donor #1 and 0.55 ± 0.20 fold change for donor #2, p < 0.01; Fig. 6c). 
Western blots confirmed these results on protein level demonstrating a significant decrease of 
p53 after 72 h of hypoxia in donor #1 and #2 (0.67 ± 0.11 fold change and 0.52 ± 0.05 fold 
change, respectively, p < 0.05; Fig. 6d). These results highlight the regulation of the 
expression of p53 by AQP1 and hypoxia in HPASMC.  
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Figure 6. AQP1 controls the expression of p53 in HPASMC. Upon transfection with GapmeR targeting 
AQP1 (25 nmol/L), mRNA (a) and protein (b) levels of p53 in two donors of HPASMC were evaluated 
relatively to control cells. Effect of hypoxia (1% O2 for 2–72 h) in HPASMC on mRNA (c) and protein (d) 
expression of p53. Representative western blots are provided (30 µg). n = 5–6 per group. Statistical analysis by 
repeated-measures ANOVA with Tukey post hoc test (a, b top), paired Student’s t test (a, b bottom), and one-
way ANOVA with Tukey post hoc test (c, d) (*p < 0.05, **p < 0.01, ***p < 0.001). 
 
Enforced expression of AQP1 enhances migration and proliferation of human 
pulmonary artery smooth muscle cells 
 
To further confirm the role of AQP1 in the context of pulmonary vascular remodelling, AQP1 
overexpression studies were performed in HPASMC. As demonstrated by the representative 
Western blot in Fig. 7a, protein expression of AQP1 was significantly increased after 
transfection with pcDNA_AQP1 (donor #1 by 13.76 ± 3.72 fold change, p < 0.001). 
Regarding the migratory potential, HPASMC overexpressing AQP1 migrated faster than 
control cells as assessed by wound-healing assay (e.g. donor #1: rate of healing in % after 7 h: 
pcDNA_empty 17.88% ± 5.52 vs. pcDNA_AQP1 24.83% ± 5.36, p < 0.001; Fig. 7b). 
Representative pictures of migrated HPASMC are provided in Supplementary Figure 3. 
Moreover, as assessed by BrdU incorporation assay, HPASMC overexpressing AQP1 showed
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enhanced proliferation rates compared to HPASMC transfected with empty control vector 
(donor #1 in absorbance at 450 nm: pcDNA_empty 0.57 ± 0.17 vs. pcDNA_AQP1 0.77 ± 
0.18, p < 0.01; Fig. 7c). All results were confirmed using a second donor of HPASMC. 
 
 
Figure 7. Enforced expression of AQP1 enhances migration and proliferation of HPASMC. Cells were 
transfected with a vector overexpressing AQP1 (pcDNA_AQP1). (a) AQP1 protein levels after transfection with 
pcDNA_AQP1 (0.25 µg) compared to empty control vector transfected cells (pcDNA_empty). A representative 
western blot is shown (30 µg). Migration (b) and proliferation (c) in AQP1 overexpressing HPASMC compared 
to control transfected cells as assessed by wound-healing (rate of healing in %) and BrdU incorporation 
(absorbance at 450 nm) assays. n = 5–6 per group. Statistical analysis by paired Student’s t test (a, c) and 
repeated-measures ANOVA with Tukey post hoc test (b) (*p < 0.05, **p < 0.01, ***p < 0.001). 
 
Silencing of AQP1 reduces right ventricular pressure in the mouse model of hypoxia-
induced PH 
 
The physiological consequences of AQP1 depletion via intervention experiments were further 
addressed in vivo by employing the hypoxia-induced mouse model of PH. The in vivo 
experiments were performed as described in the section ‘Methods’ (Fig. 8a). 
As shown in Fig. 8b, hypoxic control mice showed a significant increase in RVP compared to 
normoxic animals (in mmHg, 38.40 ± 3.71 vs. 30.33 ± 2.32, p < 0.05) confirming the 
development of PH. Repeated i.p. injections of negative control GapmeR had no effect on 
RVP, since RVP stayed significantly elevated in comparison with normoxic control. In
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contrast, treatment with GapmeR targeting AQP1 significantly reduced RVP in these mice 
compared to hypoxic GapmeR negative control mice (hypoxic GapmeR AQP1 mice 29.77 ± 
8.08 vs. hypoxic GapmeR negative control mice 41.00 ± 3.40, p < 0.01; Fig. 8b). Importantly, 
after treatment with GapmeR AQP1, RVP of these mice dropped to the same level as in 
normoxic control animals (Fig. 8b). Of note, systemic arterial pressure and haematocrit were 
not affected by GapmeR application indicating selective effects of GapmeR within the 
pulmonary circulation (Fig. 8c, d). Planimetric analysis of the ratio between right ventricular 
and left ventricular diameter including interventricular septum [RV/(LV+S)] showed a 
significant increase of the right ventricular volume following exposure to hypoxia (0.295 ± 
0.079) as compared to normoxic controls (0.183 ± 0.039, p < 0.01). Upon treatment with 
GapmeR against AQP1, the ratio was decreased (0.204 ± 0.029, p < 0.05; Fig. 8e).  
In lung tissue collected from these mice, AQP1 mRNA levels were significantly elevated after 
hypoxic exposure compared to normoxic control mice (by 1.36 ± 0.14 fold change, p < 0.01; 
Fig. 8f) being in line with Fig. 1b. Moreover, repeated i.p. injections of GapmeR targeting 
AQP1 significantly downregulated mRNA levels of AQP1 in lung tissue compared to hypoxic 
GapmeR negative control animals (hypoxic GapmeR negative control mice 1.24 ± 0.28 fold 
change vs. hypoxic GapmeR AQP1 mice 0.97 ± 0.14 fold change, p < 0.05; Fig. 8f). Treat-
ment with GapmeR AQP1 had no effect on mRNA levels of other AQPs expressed in the lung 
(AQP2-5), confirming specificity of the GapmeR design. Hypoxia, however, was able to 
significantly upregulate the expression of AQP4 and AQP5 (Supplementary Figure 4).  
Affirming the results of the mRNA expression analysis, protein expression of AQP1 was 
found to be significantly upregulated in both hypoxic and hypoxic GapmeR negative control 
mice compared to normoxic control animals (hypoxic mice, by 2.77 ± 1.23 fold change, 
hypoxic GapmeR negative control mice, by 2.90 ± 0.87 fold change, p < 0.01 and p < 0.001, 
respectively; Fig. 8g). Administration of GapmeR AQP1 tended to reduce the protein 
expression of AQP1 to levels between normoxic and hypoxic animals (hypoxic GapmeR 
AQP1 mice 2.02 ± 0.67 fold change vs. normoxic mice 1.00 ± 0.36 fold change, not 
significant; Fig. 8g).  
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Figure 8. Silencing of AQP1 reduces right ventricular pressure in the mouse model of hypoxia-induced 
PH. (a) Study design of the in vivo experiments. Four groups of eight animals each (n = 7 for hypoxia GapmeR 
negative control) were used: three groups were employed in conditions at 10% O2 for 5 weeks and, after 3 
weeks, treated either with GapmeR negative control or GapmeR AQP1 (both 10 mg/kg). Injections were 
performed intraperitoneally (i.p.) every fourth day. One group served as a normoxic control group. 
Haemodynamic assessment of the mouse model of hypoxia-induced PH shows (b) right ventricular pressure 
(RVP, in mmHg) measured by right heart catheterization (RHC), (c) systemic arterial pressure (SAP, in mmHg), 
and (d) haematocrit (%) in the three hypoxic (Hx) mouse groups compared to normoxic (Nx) animals. (e) 
Planimetric analysis of the ratio between the right and left ventricular volume including interventricular septum 
wall [RV/(LV+S)] (n = 6–8). Effect of hypoxia and GapmeR treatment on AQP1 mRNA (f) and protein (g) 
expression in lung homogenates measured by qPCR and western blot (n = 7–8). A representative western blot is 
provided (30 µg). Statistical analysis by one-way ANOVA with Tukey post hoc test (b– g) (*p < 0.05, **p < 
0.01, ***p < 0.001). 
 
2.5 DISCUSSION 
Aquaporin 1 is known to be induced by hypoxia which itself might be both a causative factor 
for and a consequence of elevated pulmonary pressure. Of interest, however, the 
physiological consequence of the manipulation of AQP1 expression has not been described in 
the context of hypoxia-induced PH so far. In this study, we confirmed the previous findings 
showing that hypoxic conditions increase the expression of AQP1 both in vitro and in vivo
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[14]. In addition, we demonstrated that manipulation of AQP1 affects the expression of the 
tumour suppressor gene p53 and influences the functional profile of pulmonary vascular cells 
on a migratory, proliferative, and apoptotic level. By employing the hypoxia-induced PH 
mouse model, we found that silencing of AQP1 by a novel chimeric antisense oligonucleotide 
technology (GapmeRs) reversed established PH. Taken together, these findings represent the 
first direct link between AQP1 and PH and provide a novel interesting target to address 
pulmonary hypertension.  
It was previously reported that AQP1 is induced by hypoxia in pulmonary artery smooth 
muscle cells. In detail, rat pulmonary artery smooth muscle cells exposed to hypoxia 
selectively increased AQP1 protein levels and, in turn, migration. Silencing of AQP1 via 
siRNA prevented the hypoxia-induced migration in these cells [13, 14]. Our initial 
experiments confirmed these findings by showing that the levels of AQP1 are increased by 
hypoxia in pulmonary artery smooth muscle cells. Of note, the observed induction of AQP1 
could not be directly linked to the stabilization of HIF-1α suggesting the involvement of other 
mechanisms [1], for example the additional influx of calcium or interaction with microRNAs 
as suggested previously [14, 22]. The multi-factorial and complex induction of AQP1 by 
hypoxia is further emphasized by variable mRNA levels between the two donors. While the 
exact mechanisms behind these findings are elusive, high protein levels and functional data 
were consistently retrieved in long-term exposed HPASMC. Moreover, in lung tissue samples 
of animals exposed to hypoxia for 5 weeks, we found a significant increase in the expression 
of AQP1 compared to normoxic controls. Levels of AQP1 could be further correlated with 
pulmonary haemodynamics indicating that mice with higher AQP1 expression levels have 
increased right ventricular pressures and vice versa. Functional experiments and a subsequent 
treatment trial emphasized that this correlation might reflect causality and not only 
association.  
Pulmonary artery smooth muscle cells showed an increased migratory response and 
dysregulation of the cell growth with development of a pro-proliferative and anti-apoptotic 
phenotype. Remodelling of small pulmonary arteries is the major factor in the pathobiology of 
PH and is, to date, not adequately addressed by modern PH-target therapies. Along that line, a 
recent publication demonstrated that genetic deletion of endothelial guanylyl cyclase-A 
receptor in mice caused pulmonary vascular remodelling, probably due to increased vascular 
cell proliferation, and PH already under normoxic conditions, since the atrial natriuretic 
peptide (ANP) cannot exert its protective effects. This experimental study underpins the 
importance for novel strategies to target or even reverse pulmonary vascular remodelling and
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PH [38]. Vascular remodelling in the pulmonary circulation is characterized by migration of 
endothelial cells reflecting angiogenesis [36], formation of a ‘‘neo-intima’’ [20], and, most 
important, uncontrolled proliferation of smooth muscle cells [5]. These changes that result in 
progressive hyperplasia of the medial vessel layer and luminal obliteration have been 
described as neoplastic-like processes [29]. Since AQPs have been associated with malignant 
transformation and the development of cancer, our results might provide a novel mechanism 
explaining similar transformation in vessels of patients with PH. One of the best characterized 
tumour suppressor genes is p53 [32] and, in the context of PH, Jacquin et al. showed that p53 
is found downregulated in the monocrotaline model of PH. Moreover, inactivation of p53 
alone was sufficient to induce the development of experimental PH [11, 16]. Another study 
demonstrated that exogenous NO has an inhibitory effect on smooth muscle cell proliferation 
via induction of p53 and p21 [17]. In our experiments, silencing of AQP1 via GapmeRs 
resulted in higher mRNA and protein expression of p53. The interaction between p53 and 
AQP1 was further highlighted in hypoxic HPASMC showing decreased p53 levels with a 
concomitant increase of AQP1 expression (Fig. 9).  
  
 
 
 
 
 
 
 
 
 
 
Figure 9. Proposed AQP1-mediated mechanism of vascular remodelling in the context of hypoxia-
induced PH. Hypoxia-induced upregulation of AQP1 leads to a reduced expression of the tumour suppressor 
p53, promoting vascular smooth muscle cell proliferation (left side). As described by Saadoun et al. [23], AQP1 
expression polarises to the leading edge of lamellipodia extension, facilitating water influx and cell migration 
(right side). 
 
In addition, enhanced p53 expression levels were found after silencing of AQP3 with shRNA 
in a non-small cell lung cancer (NSCLC) model, which was accompanied with suppressed 
tumour proliferation [39]. AQP3 knockdown reduced cellular glycerol content (AQP3 is an 
aquaglyceroporin) and mitochondrial ATP formation, which, together with a reduction in 
PCNA levels, might contribute to the inhibitive effect on tumour proliferation. Of note, the 
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importance of AQP1 for the vascular smooth muscle phenotype was highlighted in a study by 
Al Ghouleh et al., demonstrating that reactive oxygen species are channelled via AQP1 
resulting in hypertrophy, however, without affecting proliferation [2]. Furthermore, a study 
investigated the role of the C-terminal tail of AQP1 on migration and proliferation, because 
the exact mechanism by which AQP1 facilitates these two processes remains unclear [13]. In 
this setting, the C-terminal was required, since its deletion in AQP1 overexpressing rat 
smooth muscle cells abolished the effect on both migration and proliferation. They concluded 
that the possible AQP1-mediated mechanisms include association of factors or proteins with 
the C-terminal. The exact mechanism how AQP1 executes its function in this context, 
however, remains elusive and it will be difficult, in general, to unravel the underlying 
molecular mechanisms that act at the interface of hypoxia, AQP1, and PH.  
Another link between AQP1 and proliferation was provided by data on adult carotid body 
cells, which were observed to proliferate less under hypoxic conditions when analysed in 
AQP1 knockout mice. Microarray data further revealed alterations in several proliferation-
regulating genes suggesting that AQP1 modifies the expression of key cell cycle proteins [6].  
In a next step, we tried to translate these in vitro findings by antagonizing AQP1 in an 
experimental model for PH. Animal models used to investigate PH have major limitations and 
only partially mimic human disease [8]. However, the hypoxia-induced mouse model is one 
of the best-established models for PH and, in the context of AQP1 that is strongly driven by 
hypoxic conditions, represents a suitable in vivo model. Silencing of AQP1 was achieved by 
administration of GapmeRs directed against AQP1. GapmeRs are single-stranded antisense 
oligonucleotides that catalyse the RNase H mediated degradation of complementary RNA 
targets and are active both in vitro and in vivo. To ensure enhanced stability and high target 
affinity, GapmeRs are composed of LNA-modified oligonucleotides flanking a central gap of 
DNA [33]. The usage of GapmeRs to target transcripts of genes of interest in vivo has been 
shown previously [31].  
In this study, repeated intraperitoneal application of GapmeRs resulted in antagonizing of 
AQP1 and reversed the hypoxia-induced elevation of the pulmonary pressure. This is, to the 
best of our knowledge, the first report on the successful targeting of AQP1 in vivo through 
GapmeRs. In turn, as a consequence of reduced AQP1 expression in lung tissue, right 
ventricular pressure in animals exposed to hypoxia was reduced to levels of normoxic control 
animals. Performing additional experiments measuring mRNA levels of AQP2-5 in whole 
tissue from lungs in our GapmeR mouse setting of hypoxia-induced PH confirmed specificity 
of GapmeR for AQP1, where hypoxia was able to significantly upregulate the expression of
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AQP4 and AQP5 (Supplementary Figure 4). Furthermore, these results indicate that there was 
no compensational feedback regulation of other AQP subsets due to GapmeR treatment. A 
limitation of this study is the near absence of right ventricular hypertrophy in the Hx GapmeR 
neg. ctl group. This might be explained by a combination of methodical limitations of applied 
morphometric analysis and the relatively high biological variation, which was observed in our 
hypoxia-induced PH mouse model. Although this mouse model is frequently applied, it is 
supposed to be a mild one in terms of RVP increase, RVH, and pulmonary vascular 
remodelling [15]. However, RVP was significantly elevated in this group after hypoxic 
exposure. Newly established animal models for hypoxia-induced PH, e.g. the Sugen/hypoxia 
[19], were shown to induce a more pronounced pathological cardiorespiratory phenotype. 
Nevertheless, our data indicate that the pharmacological use of GapmeRs to target AQP1 
reverses hypoxia-induced elevated pulmonary pressure and might treat vascular remodelling. 
The use of these novel antisense oligonucleotides could be limited by non-specific binding to 
proteins and off-target effects such as hepatotoxicity [12]. In our experiments, however, no 
such effects were observed indicating that GapmeR therapy is well tolerated and feasible.  
In conclusion, this is the first report of AQPs in the context of PH. The identification of AQP1 
expression and its functional characterization upon exposure to hypoxia unravels novel and 
important insights in the pathogenesis of pulmonary vascular remodelling. The therapeutic 
application of innovative antisense oligonucleotides resulted in successful antagonization of 
AQP1 and reversed experimental PH. However, it remains elusive at the moment whether 
these results might offer a future opportunity to target AQP1 in the lungs to prevent vascular 
remodelling in a selected cohort of patients with PH in the context of chronic lung disease. 
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2.7 SUPPLEMENTARY MATERIAL 
Supplementary Tables 
 
Supplementary Table 1. Antisense LNA GapmeR sequences used for silencing of AQP1. + = prefix for LNA. 
Modification: phosphorothioate backbone. 
GapmeR Sequence LNA content 
GapmeR negative ctl 5’ – +G+A+C TAA TGC ATT +A+T+C – 3’ 6 
GapmeR AQP1 5’ – +T+G+T CAG AGT GTC +T+A+C – 3’ 6 
 
 
 
Supplementary Table 2. Primer sequences used for cloning of AQP1 and the validation of different genes by 
qPCR. hsa: Homo sapiens. mmu: Mus musculus. 
AQP1 cloning Primer forward Primer reverse 
Nested PCR 5’ – ATG GCC AGC GAG TTC AAG – 3’ 5’ – CTA TTT GGG CTT CAT CTC C – 3’ 
Reverse PCR 
5’ – AAA CTT AAG CTT GCC GCC ATG GCC 
AGC GAG TTC AAG – 3’ 
5’ – CTA GAC TCG AGC TAT TTG GGC TTC 
ATC TCC – 3’ 
 
Gene Primer forward Primer reverse 
β-actin (hsa, mmu) 5’ – TCA AGA TCA TTG CTC CTC CTG AG – 3’ 5’ – TCC TGC TTG CTG ATC CAC ATC – 3’ 
AQP1 (hsa) 5’ – ACC TCC TGG CTA TTG ACT ACA C – 3’ 5’ – GGT TGC TGA AGT TGT GTG TGA TC – 3’ 
AQP1 (mmu) 5’ – ACT TGG CCG CAA TGA CCT GG – 3’ 5’ – CAG AGT GCC AAT GAT CTC AAT GC – 3’ 
p53 (hsa) 5’ – AGC CAC CTG AAG TCC AAA AAG – 3’ 5’ – CCC TTC TGT CTT GAA CAT GAG – 3’ 
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Supplementary Figures 
 
 
 
Supplementary Figure 1. Representative pictures of HPASMC (donors #1 and #2) migrated for 7 h in 
normoxia after transfection with GapmeR targeting AQP1 compared to non-transfected or GapmeR negative 
control transfected cells. 
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Supplementary Figure 2. Representative pictures of HPASMC migrated for 7 h in hypoxia (Hx) after 
transfection with GapmeR targeting AQP1 compared to non-transfected or GapmeR negative control transfected 
cells.  
 
 
 
Supplementary Figure 3. Representative pictures of HPASMC migrated for 7 h after transfection with AQP1 
overexpressing vector (pcDNA_AQP1) compared to empty control transfected cells (pcDNA_empty).  
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Supplementary Figure 4. Lung mRNA expression of AQP2-5 in the mouse model of hypoxia-induced PH. 
Effect of hypoxia and GapmeR treatment on AQP4 (a) and AQP5 (b) in lung homogenates measured by qPCR. 
The levels of AQP2 and AQP3 have not been added since both revealed poor Ct values (> 32). n = 7-8. 
Statistical analysis by one-way ANOVA with Tukey post hoc test (*p < 0.05, **p < 0.01, ***p < 0.001).  
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 SYNTHESIS 3
3.1 MAIN FINDINGS AND IMPLICATIONS 
AQP1 is known to be induced by hypoxia which itself might be both a causative factor for 
and a consequence of elevated pulmonary pressure. Of interest, however, the physiological 
consequence of the manipulation of AQP1 expression has not been described in the context of 
hypoxia-induced PH so far and our study provides the first evidence for a functional role of 
AQP1 in the disease by employing an intervention model in mice with hypoxia-induced PH. 
In this study, we confirmed previous findings showing that (i) hypoxia increases the 
expression of AQP1 both in vitro, most prominently in HPASMC, and in vivo in the hypoxia-
induced mouse model of PH.71 In addition, we demonstrated that (ii) manipulation of AQP1 
affects the expression of the tumour suppressor gene p53 in HPASMC with decreased levels 
after hypoxic exposure and increased levels after silencing of AQP1 by a novel chimeric 
antisense oligonucleotide technology (GapmeRs). p53 has pro-apoptotic and growth-
suppressive effects by holding the cell cycle at the G1/S regulation point.40 Therefore, high 
p53 induces apoptosis and cell cycle arrest which is in agreement with the functional data 
seen in HPASMC: Here, (iii) AQP1 influences the functional profile of pulmonary vascular 
cells via controlling a migratory, pro-proliferative, and anti-apoptotic phenotype of HPASMC 
as assessed by silencing and overexpression experiments. Inhibition of AQP1 via GapmeRs 
decreased the migratory and proliferative response while increasing apoptosis and AQP1 
overexpression resulted in enhanced proliferation and migration. By employing the (iv) 
hypoxia-induced PH mouse model, our data indicate that the pharmacological use of 
GapmeRs to target AQP1 reverses hypoxia-induced elevated pulmonary pressure and might 
treat vascular remodelling since planimetric analysis of the Fulton index [RV/(LV+S)]81 
revealed a decrease in right ventricular hypertrophy in GapmeR AQP1 treated hypoxic mice.  
With this doctoral thesis, I have extensively addressed the expression and function of AQP1 
in the context of hypoxia-induced PH. Our findings offer new insights and represent the first 
direct link between PH and AQP1, possibly providing an interesting novel target to address 
PH. We present data showing that AQP1 has an important functional role in the development 
of pulmonary vascular remodelling in hypoxia-induced PH. Since vascular remodelling is due 
to enhanced proliferation of pulmonary artery smooth muscle cells and is currently not 
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sufficiently addressed by PH therapies, these data have implications both for our pathogenetic 
understanding and novel therapeutic approaches. 
 
3.2 LIMITATIONS 
The research addressed in this thesis faces several limitations that need to be considered. A 
major limitation of the present work is the absence of a mechanistic explanation how AQP1 
executes its function in the context of hypoxia-induced PH. The exact mechanism remains 
elusive and it will be difficult, in general, to unravel the underlying molecular mechanisms 
that act at the interface of hypoxia, AQP1, and PH. 
We suggest that AQP1 might act through interaction with the tumour suppressor p53, which 
has repeatedly been associated with the development of pulmonary hypertension. This 
connection is well elaborated but, whether, further upstream, other processes might be 
additionally involved, is part of an interesting hypothesis but remains unclear to date. Jacquin 
et al. showed that p53 is found downregulated in the monocrotaline model of PH.41 Moreover, 
inactivation of p53 alone was sufficient to induce the development of experimental PH and 
another study demonstrated that exogenous NO has an inhibitory effect on smooth muscle cell 
proliferation via induction of p53 and p21.42, 43 Additionally, enhanced p53 mRNA as well as 
protein levels were found after silencing of AQP3 with shRNA in a non-small cell lung 
cancer (NSCLC) model, which was accompanied with suppressed tumour proliferation. 
AQP3 knockdown reduced cellular glycerol content (AQP3 is a aquaglyceroporin) and 
mitochondrial ATP formation, which, together with a reduction in PCNA levels, might 
contribute to the inhibitive effect on tumour proliferation.74 
In the light of other findings that tried to tie AQP1 function to several stimuli, Legget et al. 
showed that hypoxia induces intracellular calcium concentration in arterial smooth muscle 
cells, which, in turn, results in increased AQP1 protein levels and cell migration.71 Al 
Ghouleh et al. highlighted the importance of AQP1 for the vascular smooth muscle phenotype 
by demonstrating that reactive oxygen species (ROS) are channelled via AQP1.75 To address 
this issue, we performed H2O2 experiments on the role of ROS. These experiments have not 
shown evidence for a pathogenetic role of ROS in our setting (Fig. 1-3). Considering the 
results from Al Ghouleh et al. that showed an effect of ROS on smooth muscle cell 
hypertrophy, however, without affecting proliferation, this is not an unexpected finding. 
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Figure 1. Stimulation with exogenous H2O2 (50 µmol/L) for 24 h does not affect O2- production in both 
donors of GapmeR transfected HPASMC. Adopted L-012 (400 µmol/L) chemiluminescence assay was 
performed immediately (0 min) or after 10 min, 20 min, and 30 min as described by Al Ghouleh et al.75 n = 3. 
Statistical analysis by Friedman test with Dunns post hoc test. 
 
  
Figure 2. Stimulation with exogenous H2O2 (50 
µmol/L) for 24 h does not have an effect on migration 
in GapmeR transfected HPASMC. Migration was 
assessed after 3 h, 5 h, and 7 h. n = 3. Statistical 
analysis by Friedman test with Dunns post hoc test. 
Figure 3. Stimulation with exogenous H2O2 (50 
µmol/L) for 24 h does not have an effect on 
proliferation in GapmeR transfected HPASMC. 
n = 5. Statistical analysis by Friedman test with 
Dunns post hoc test. 
 
Furthermore, a study investigated the role of the C-terminal tail of AQP1 on migration and 
proliferation since the exact mechanism by which AQP1 facilitates these two processes 
remains unclear.72 In summary, the authors showed that the C-terminus is required since its 
deletion in AQP1 overexpressing rat smooth muscle cells abolished the effect on both 
migration and proliferation. As a consequence, they proposed that AQP1 mediates its function 
via factors or proteins associated with the C-terminal tail, however, not offering an exact 
mechanism and only being vague. 
 
Moreover, microarray data further revealed alterations in several proliferating-regulating 
genes suggesting that AQP1 modifies the expression of key cell cycle proteins.76 Although 
this breakthrough paper revealed a rather tight connection between AQP1 and its role in 
proliferation by affecting cell cycle progression, it also fails to unravel the exact mechanistic 
insights on how AQP1 executes its function in this context. In consideration of this work and
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a recently published paper by our group on the role of lncRNA MALAT1 in smooth muscle 
cell proliferation,39 we tried to address a similar setting via measuring mRNA levels of cyclin-
dependent kinase inhibitors (CDKi: p15, p16, p18, p19, p21, p27, and p57), cyclin D1 and E1, 
and NFK-B1, respectively, in HPASMC transfected with GapmeR targeting AQP1. Only the 
expression levels of cyclin E1 were significantly altered (Fig. 4). However, as a representative 
protein of the S phase in the cell cycle, we expected it to be downregulated when AQP1 is 
silenced. This indicates that AQP1 does not, at least in our setup, act through CDKi or 
selected cyclins. 
 
 
Figure 4. mRNA expression of selected cyclin-dependent kinase inhibitors (CDKi), cyclin D1 and E1, and 
NFK-B1 in GapmeR AQP1 transfected HPASMC. The expression levels of non-transfected control cells were 
set to 1 (shown as dashed line). n = 5. Statistical analysis by one-way ANOVA with Tukey post hoc test (*p < 
0.05 compared to GapmeR AQP1 (cyclin E1), ***p < 0.001 compared to non-transfected control cells). 
 
All these studies and additional experiments try to explain the AQP1-mediated mechanism in 
the context of hypoxia-induced PH, even though without being a transcription factor. 
However, experimental proofs were beyond the scope of this work, but, nevertheless, are a 
prominent issue that should be subjected to follow-up in a further project. Despite the fact that 
the exact molecular players providing the mechanistic interaction have not been unravelled so 
far, our experiments highly suggest a causal link between hypoxia, AQP1 and PH. 
 
Animal models used to investigate PH, although they support several mechanisms identified 
in cell culture work, are of limited value and only partially mimic human disease.82 However, 
the hypoxia-induced mouse model is one of the best-established models for PH and, in the 
context of AQP1 that is strongly driven by hypoxic conditions, represents a suitable in vivo 
model. Nevertheless, another limitation of our study is the near absence of right ventricular 
hypertrophy in the hypoxic GapmeR control group. This might be explained by a combination 
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of methodical limitations of applied morphometric analysis and the relatively high biological 
variation, which was observed in our hypoxia-induced PH mouse model. Although this mouse 
model is frequently used, it is supposed to be a mild one in terms of RVP increase, RVH, and 
pulmonary vascular remodelling.83 Repeated i.p. injections of GapmeRs lead to a systemic 
knockout of AQP1 in the mouse model and not much is known about the pharmacokinetics of 
GapmeRs. It might have been beneficial to apply more often or even locally and specifically 
in the lungs, e.g. through a nebulizer. However, RVP was significantly elevated in this group 
after hypoxic exposure. Newly established animal models for hypoxia-induced PH, e.g. the 
new gold standard Sugen/hypoxia model,84 were shown to induce a more pronounced 
pathological cardiorespiratory phenotype and are more frequently used nowadays. In this 
context, unfortunately, we were not able to provide data on immunohistochemistry (IHC) that 
may have further strengthened our hypothesis about the involvement of AQP1 in vascular 
remodelling in hypoxia-induced PH where one would expect reduced vascular remodelling in 
the GapmeR AQP1 treated hypoxic animals. Using IHC for established targets of smooth 
muscle cell proliferation (e.g. α-smooth muscle actin) and markers for endothelial (e.g. von 
Willebrand factor) and adventitial layer (e.g. collagen), the degree of vascular remodelling in 
the pulmonary vessels could have been assessed. The infeasibility on conducting IHC was due 
to technical and methodological restrictions. 
 
Another issue that needs to be dealt with is the lack of reduction in apoptosis in AQP1 
overexpressing HPASMC. Contrary to GapmeR AQP1 transfected cells, no effects were 
observed on the spontaneous rate of apoptosis in these cells. While these data suggest that 
overexpression of AQP1 has no effect on spontaneous apoptosis of vascular smooth muscle 
cells, one cannot exclude that AQP1 alters resistance of cells to apoptosis when exposed to 
strong inducers of cell death. Such stimuli might include camptothecin (CPT), which 
addresses the intrinsic apoptotic pathway via inhibition of topoisomerase I, and Fas ligand 
(FasL), which addresses the extrinsic apoptotic pathway via binding to plasma membrane 
spanning death receptors like Fas receptor (FasR).  
 
3.3 OUTLOOK 
As extensively discussed in chapter 3.2 ‘Limitations’, a big goal would be to identify the 
underlying AQP1-mediated molecular mechanisms that lead to pulmonary vascular
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remodelling. Furthermore, researchers are very interested in finding new specific inhibitors, 
which would make it easier to investigate the direct function of AQPs in general. So far, 
studies of the phenotype of AQP-knockout mice have provided most of the information on 
AQP physiology and function. Compelling evidence from studies using AQP-knockout mice 
and from humans with AQPs loss-of-function mutations suggest that AQPs are important 
research tools and drug targets for the treatment of human diseases, having broad 
implementations not only in the field of pulmonology but also in different clinical therapies 
such as nephrology, neurology, oncology, and ophthalmology. The identification of AQP 
modulators, however, has turned out to be unexpectedly challenging and the poor drugability 
of AQPs may be, among others, due to the small size of the functional AQP monomer and its 
very small pore diameter, which prevents the access of small molecules. As long as no 
suitable AQP inhibitors are discovered, alternative strategies are required such as the use of 
novel antisense oligonucleotides like GapmeRs or even the new promising targeted gene 
editing tool CRISPR/Cas9 system, which has generated considerable excitement in the 
scientific community. On grounds of the above and based on my studies, one should consider 
the following additional questions that should be addressed by further experiments: (i) Does 
the inhibition of AQP1 result in reversal of the vascular remodelling of pulmonary arterial 
vessels, e.g. by employing IHC? (ii) Is the application of GapmeRs to silence AQP1 a feasible 
clinical approach to deliver and to influence targeted cells, e.g. in the lung? These in vivo 
experiments will clarify the role of AQP1 in the pathogenesis of PH and address the question 
whether GapmeR directed against AQP1 can be used as a novel and promising drug to treat 
hypoxia-induced PH. 
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APPENDIX 
ABBREVIATIONS 
ANOVA analysis of variance 
ANP atrial natriuretic peptide 
AQP(s) aquaporin(s) 
ASO antisense oligonucleotides 
BMPR2 bone morphogenetic protein receptor type 2 
bp base pair 
BrdU 5-bromo-2-deoxyuridine 
CDKi cyclin-dependent kinase inhibitors 
cDNA complementary DNA 
cGMP cyclic guanosine monophosphate 
CHIP28 channel-like integral membrane protein 28 kDa 
CPT camptothecin 
Ct threshold cycle 
ECs endothelial cell 
Epo erythropoietin 
ET-1 endothelin-1 
FasL Fas ligand 
FasR Fas receptor 
H2O2 hydrogen peroxide 
HgCl2 mercury chloride 
HIF-1α hypoxia-inducible factor 1 alpha 
HPAEC human pulmonary artery endothelial cells 
HPASMC human pulmonary artery smooth muscle cells 
IHC immunohistochemistry 
IL-6 interleukin-6 
i.p. intraperitoneal 
kDa kilodalton 
LNA locked nucleic acid
Abbreviations 
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lncRNA long non-coding RNAs 
NSCLC non-small cell lung cancer 
MALAT1 metastasis-associated lung adenocarcinoma 
transcript 1 
miRNA microRNA 
mmHg millimetre mercury 
mPAP mean pulmonary arterial pressure 
NO nitric oxide 
PAH pulmonary arterial hypertension 
PCNA proliferating cell nuclear antigen 
PDE5 phosphodiesterase-5 
PH pulmonary hypertension 
qPCR quantitative polymerase chain reaction 
RNAi RNA interference 
ROS reactive oxygen species 
RVH right ventricular hypertrophy 
RVP right ventricular pressure 
SAP systemic arterial pressure 
SD standard deviation 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel 
electrophoresis 
shRNA short hairpin RNA 
siRNA small interfering RNA 
SMCs smooth muscle cells 
TBS-T Tris-buffered saline containing 0.1% Tween 20 
VEGF vascular endothelial growth factor 
WHO World Health Organization 
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